Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jan 18;82(2):291–294. doi: 10.1054/bjoc.1999.0917

Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature

J Pelgrims 1, F De Vos 1, J Van den Brande 1, D Schrijvers 1, A Prové 1, J B Vermorken 1
PMCID: PMC2363270  PMID: 10646879

Abstract

Ifosfamide is an alkylating agent used in the treatment of a variety of solid tumours. Ten to 15% of patients treated with ifosfamide develop an encephalopathy. Methylene blue (MB) may be used in the treatment of this encephalopathy. The purpose of this study was to evaluate the neuroprotective effect of MB in these patients and to review the literature. Between 1993 and 1997, 52 patients (age 16–77 years) with solid tumours were treated with ifosfamide in dosages ranging from 3 to 5 g m−2q3w when given in combination schedules and up to 12 g m−2q4w when given as a single agent. Twelve patients developed central nervous system (CNS) depression, defined as National Cancer Institute Common Toxicity Criteria (NCI-CTC) neurocortical toxicity grade 2 or higher. Eight were treated with MB at a dose of 6 × 50 mg day−1intravenously (i.v.). Four recovered fully within 24 h, two recovered partially after 24 h and completely after 48 h while two recovered only after 72 h. Four patients did not receive MB and all recovered only after 48 h. Three patients received prophylaxis with MB at a dose of 4 × 50 mg day−1i.v. for the subsequent chemotherapy cycles. Two developed milder encephalopathy; one had no CNS depression at all. We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy. Our findings suggest that it may also be used as a prophylactic agent. © 2000 Cancer Research Campaign

Keywords: ifosfamide, methylene blue, encephalopathy

Full Text

The Full Text of this article is available as a PDF (44.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aeschlimann C., Cerny T., Küpfer A. Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Drug Metab Dispos. 1996 Dec;24(12):1336–1339. [PubMed] [Google Scholar]
  2. Aeschlimann C., Küpfer A., Schefer H., Cerny T. Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy. Drug Metab Dispos. 1998 Sep;26(9):883–890. [PubMed] [Google Scholar]
  3. Alonso J. L., Nieto Y., López J. A., Martín M., Díaz-Rubio E. Ifosfamide encephalopathy and methylene-blue: a case report. Ann Oncol. 1996 Aug;7(6):643–644. doi: 10.1093/oxfordjournals.annonc.a010686. [DOI] [PubMed] [Google Scholar]
  4. Cerny T., Castiglione M., Brunner K., Küpfer A., Martinelli G., Lind M. Ifosfamide by continuous infusion to prevent encephalopathy. Lancet. 1990 Jan 20;335(8682):175–175. doi: 10.1016/0140-6736(90)90053-8. [DOI] [PubMed] [Google Scholar]
  5. Curtin J. P., Koonings P. P., Gutierrez M., Schlaerth J. B., Morrow C. P. Ifosfamide-induced neurotoxicity. Gynecol Oncol. 1991 Sep;42(3):193–192. doi: 10.1016/0090-8258(91)90344-5. [DOI] [PubMed] [Google Scholar]
  6. Demandt M., Wandt H. Erfolgreiche Behandlung von Ifosfamid-bedingten zentralnervösen Nebenwirkungen mit Methylenblau. Dtsch Med Wochenschr. 1996 Apr 26;121(17):575–575. [PubMed] [Google Scholar]
  7. DiMaggio J. R., Brown R., Baile W. F., Schapira D. Hallucinations and ifosfamide-induced neurotoxicity. Cancer. 1994 Mar 1;73(5):1509–1514. doi: 10.1002/1097-0142(19940301)73:5<1509::aid-cncr2820730531>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  8. Ferrero J. M., Eftekari P., Largillier R., Dreyfus G., Namer M. Traitement d'une encéphalopathie à l'ifosfamide par le bleu de méthylène. Bull Cancer. 1995 Jul;82(7):598–599. [PubMed] [Google Scholar]
  9. Harpey J. P., Charpentier C., Coudé M. Methylene-blue for riboflavin-unresponsive glutaricaciduria type II. Lancet. 1986 Feb 15;1(8477):391–391. doi: 10.1016/s0140-6736(86)92361-5. [DOI] [PubMed] [Google Scholar]
  10. Hrushesky W. J., Olshefski R., Wood P., Meshnick S., Eaton J. W. Modifying intracellular redox balance: an approach to improving therapeutic index. Lancet. 1985 Mar 9;1(8428):565–567. doi: 10.1016/s0140-6736(85)91218-8. [DOI] [PubMed] [Google Scholar]
  11. Kaijser G. P., Beijnen J. H., Bult A., Underberg W. J. Ifosfamide metabolism and pharmacokinetics (review). Anticancer Res. 1994 Mar-Apr;14(2A):517–531. [PubMed] [Google Scholar]
  12. Koschuth A., Späth-Schwalbe P. E., Possinger K. Methylenblau bei Ifosfamidinduzierter Enzephalopathie. Dtsch Med Wochenschr. 1996 Sep 27;121(39):1210–1210. [PubMed] [Google Scholar]
  13. Kurowski V., Cerny T., Küpfer A., Wagner T. Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Cancer Res Clin Oncol. 1991;117 (Suppl 4):S148–S153. doi: 10.1007/BF01613221. [DOI] [PubMed] [Google Scholar]
  14. Küpfer A., Aeschlimann C., Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol. 1996;50(4):249–252. doi: 10.1007/s002280050102. [DOI] [PubMed] [Google Scholar]
  15. Küpfer A., Aeschlimann C., Wermuth B., Cerny T. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet. 1994 Mar 26;343(8900):763–764. doi: 10.1016/s0140-6736(94)91839-2. [DOI] [PubMed] [Google Scholar]
  16. Merimsky O., Reider-Groswasser I., Wigler N., Chaitchik S. Encephalopathy in ifosfamide-treated patients. Acta Neurol Scand. 1992 Nov;86(5):521–525. doi: 10.1111/j.1600-0404.1992.tb05136.x. [DOI] [PubMed] [Google Scholar]
  17. Pratt O. E., Rooprai H. K., Shaw G. K., Thomson A. D. The genesis of alcoholic brain tissue injury. Alcohol Alcohol. 1990;25(2-3):217–230. doi: 10.1093/oxfordjournals.alcalc.a044995. [DOI] [PubMed] [Google Scholar]
  18. Zulian G. B., Tullen E., Maton B. Methylene blue for ifosfamide-associated encephalopathy. N Engl J Med. 1995 May 4;332(18):1239–1240. doi: 10.1056/NEJM199505043321817. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES